PipelineReview.com - TCR T-Cells and Antibodies

Show Cart

TCR T-Cells and Antibodies

Results 1 - 10 of 16

Jun 2018 Report Package: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin

(Discount: 40.00%)

Jun 2018 Competitor Analysis: MAGE-A-Targeted Immunotherapy

Jun 2018 Competitor Analysis: NY-ESO-1-Targeted Immunotherapy

Jun 2018 Competitor Analysis: hTERT-Targeted Immunotherapy

Jun 2018 Competitor Analysis: WT1-Targeted Immunotherapy

Jun 2018 Competitor Analysis: PRAME-Targeted Immunotherapy

May 2018 Report Package: TCR-Based Antibody and T-Cell Immunotherapy

(Discount: 33.33%)

May 2018 Competitor Analysis: Survivin-Targeted Immunotherapy

May 2018 TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Jan 2018 Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Start
Prev
1
2
Next
End

Shopping cart

Cart empty

Latest report

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Featured Products

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Latest Target Pipeline

CD38-Targeted Antibody & Cell Therapy

Shopping cart

Cart empty

Latest report

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Featured Products

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Latest Target Pipeline

CD38-Targeted Antibody & Cell Therapy

La Merie Biologics

FREE Weekly News Bulletin

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing